Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Beyond M&As: will 2020 by the year of the spin-out?

Last year saw extensive M&A activity in pharma, centred around large scale multi-billion-dollar megamergers. With the year of the megamerger now behind us, what will be the new commercial trend of 2020? Allie Nawrat explores big pharma’s move to spin-off portions of its portfolio and its benefits for the industry.

Close
Close
Close

Go Top